Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Partial p53 reactivation is sufficient to induce cancer regression

Fig. 5

E177R activation induces regression of p53-deficient Burkitt-like B cell lymphomas. a EμMyc; Trp53LSL-E177R/− lymphomas with (n = 13) or without (n = 25) the Rosa26CreERT2 transgene were transplanted into immunocompetent 129/B6 F1 hybrid mice and, after confirmation of disease onset, treated 1 week with daily i.p. injections of 1 mg tamoxifen. Mice were euthanized when humane endpoint criteria were reached. Shown is the Kaplan-Meier survival graph with Log-rank (Mantel-Cox) test. b EμMyc; Rosa26CreERT2/+ lymphomas were transplanted as in a and treated 1 week with daily i.p. injections of either corn oil (mock; n = 7) or 1 mg tamoxifen (Tam; n = 8). Shown is the Kaplan-Meier survival graph with Log-rank (Mantel-Cox) test. c-f Mice transplanted with EμMyc; Trp53LSL-E177R/−; Rosa26CreERT2 lymphomas were sacrificed before, day 2 and 7 after start of tamoxifen (Tam) treatment or upon relapse. Samples were analyzed by immunohistochemistry for BrdU (proliferation), p53 and apoptosis (cleaved caspase-3 CC3, TUNEL). c Representative images. d-e Quantification of immunohistochemistry. d Proliferation (BrdU). e Apoptosis (cleaved caspase-3, CC3). All bar graphs show the mean positivity index ±SD; datapoints represent individual fields of view (1000X1000 pixel each) from n = 3 mice sacrificed at each time point; reported are P-values of 1way ANOVA and indicated pairwise comparisons (Dunnett’s multiple comparisons test). f Representative images of hepatic lymphoma infiltrates in the periportal space stained for p53 and apoptosis (cleaved caspase-3, CC3) at indicated time points after Tam treatment

Back to article page